KR20220084109A - 항암제 노출 방지 방법 - Google Patents
항암제 노출 방지 방법 Download PDFInfo
- Publication number
- KR20220084109A KR20220084109A KR1020227016126A KR20227016126A KR20220084109A KR 20220084109 A KR20220084109 A KR 20220084109A KR 1020227016126 A KR1020227016126 A KR 1020227016126A KR 20227016126 A KR20227016126 A KR 20227016126A KR 20220084109 A KR20220084109 A KR 20220084109A
- Authority
- KR
- South Korea
- Prior art keywords
- solution
- hypochlorous acid
- anticancer
- aqueous solution
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 70
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 39
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 24
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 22
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims abstract description 22
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 16
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 15
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 15
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 15
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 11
- 229960004316 cisplatin Drugs 0.000 claims abstract description 11
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 11
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 11
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 11
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 11
- 229960001428 mercaptopurine Drugs 0.000 claims abstract description 11
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 11
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 11
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002707 bendamustine Drugs 0.000 claims abstract description 10
- 229960004528 vincristine Drugs 0.000 claims abstract description 10
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims abstract description 10
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 86
- 239000007864 aqueous solution Substances 0.000 claims description 47
- 238000005507 spraying Methods 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 13
- 239000007921 spray Substances 0.000 claims description 5
- 239000003595 mist Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 description 59
- 238000000354 decomposition reaction Methods 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000126 substance Substances 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 239000008213 purified water Substances 0.000 description 16
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 14
- 238000012790 confirmation Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 239000012488 sample solution Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000005708 Sodium hypochlorite Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- -1 melparan Chemical compound 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
- A62D3/30—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents
- A62D3/38—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by oxidation; by combustion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/14—Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances including air-liquid contact processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/02—Inorganic materials
- A61L2101/06—Inorganic materials containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2209/00—Aspects relating to disinfection, sterilisation or deodorisation of air
- A61L2209/10—Apparatus features
- A61L2209/13—Dispensing or storing means for active compounds
- A61L2209/132—Piezo or ultrasonic elements for dispensing
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Emergency Management (AREA)
- Business, Economics & Management (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019203722 | 2019-11-11 | ||
| JPJP-P-2019-203722 | 2019-11-11 | ||
| PCT/JP2020/041778 WO2021095696A1 (ja) | 2019-11-11 | 2020-11-09 | 抗がん剤曝露防止方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220084109A true KR20220084109A (ko) | 2022-06-21 |
Family
ID=75912915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227016126A Ceased KR20220084109A (ko) | 2019-11-11 | 2020-11-09 | 항암제 노출 방지 방법 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPWO2021095696A1 (enrdf_load_stackoverflow) |
| KR (1) | KR20220084109A (enrdf_load_stackoverflow) |
| CN (1) | CN114728189A (enrdf_load_stackoverflow) |
| TW (1) | TW202123978A (enrdf_load_stackoverflow) |
| WO (1) | WO2021095696A1 (enrdf_load_stackoverflow) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6117973B2 (enrdf_load_stackoverflow) | 1977-04-07 | 1986-05-10 | Kajima Corp | |
| US6092445A (en) | 1999-04-29 | 2000-07-25 | Skackelford; Jerry Lynn | Telescoping die holder |
| JP2014217555A (ja) | 2013-05-08 | 2014-11-20 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎａｎｄ Ｃｏｍｐａｎｙ | 輸液チューブセットおよびその使用方法 |
| KR20180122023A (ko) | 2016-03-28 | 2018-11-09 | 어플라이드 머티어리얼스, 인코포레이티드 | 서셉터 지지부 |
| KR20180126316A (ko) | 2017-05-17 | 2018-11-27 | 엘지전자 주식회사 | 스마트 비데 및 이를 포함하는 제어 시스템 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9323399D0 (en) * | 1993-11-12 | 1994-01-05 | Univ Newcastle Ventures Ltd | Pharmaceutical formulations |
| JP4007760B2 (ja) * | 1997-11-11 | 2007-11-14 | タカラバイオ株式会社 | 藻類由来の生理活性物質を利用した医薬、食品または飲料 |
| JP2003169842A (ja) * | 2001-12-04 | 2003-06-17 | Sony Corp | 次亜塩素酸水溶液による殺菌方法および殺菌装置 |
| AU2003230770A1 (en) * | 2002-03-28 | 2003-10-13 | Oxis International, Inc. | Neuroprotectant methods, compositions, and screening methods thereof |
| JP2006081802A (ja) * | 2004-09-17 | 2006-03-30 | Technomax:Kk | 次亜塩素酸含有水による悪臭物質収容施設の殺菌・消臭方法及びそれに用いる装置 |
| TW200714276A (en) * | 2005-10-12 | 2007-04-16 | Chiayi University | Method for producing anti-tumor compound, piceatannol |
| MX386504B (es) * | 2009-06-15 | 2025-03-19 | Sanfer Farma S A P I De C V | Solucion que contiene acido hipocloroso y metodos para usar la misma. |
| CA2796029A1 (en) * | 2010-04-14 | 2011-10-20 | Hypo-Stream Limited | Device for preparing dilute disinfectant solution |
| JP5613900B2 (ja) * | 2010-10-27 | 2014-10-29 | 学校法人 岩手医科大学 | 光触媒水性組成物及び該組成物を用いた抗がん剤分解法 |
| JP3166522U (ja) * | 2010-12-24 | 2011-03-10 | ナナイロ株式会社 | 除菌消臭用噴霧器 |
| CN105246554B (zh) * | 2013-06-25 | 2019-07-26 | 株式会社田村特科 | 抗癌剂分解方法及抗癌剂分解装置 |
| JP2018516964A (ja) * | 2015-06-09 | 2018-06-28 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドＳｕｎ Ｐｈａｒｍａ Ａｄｖａｎｃｅｄ Ｒｅｓｅａｒｃｈ Ｃｏｍｐａｎｙ Ｌｉｍｉｔｅｄ | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 |
| JP2020174900A (ja) * | 2019-04-18 | 2020-10-29 | 緒方 康夫 | 抗癌剤を分解するための薬剤および方法 |
-
2020
- 2020-11-09 KR KR1020227016126A patent/KR20220084109A/ko not_active Ceased
- 2020-11-09 WO PCT/JP2020/041778 patent/WO2021095696A1/ja not_active Application Discontinuation
- 2020-11-09 CN CN202080078466.7A patent/CN114728189A/zh active Pending
- 2020-11-09 JP JP2021556088A patent/JPWO2021095696A1/ja active Pending
- 2020-11-10 TW TW109139151A patent/TW202123978A/zh unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6117973B2 (enrdf_load_stackoverflow) | 1977-04-07 | 1986-05-10 | Kajima Corp | |
| US6092445A (en) | 1999-04-29 | 2000-07-25 | Skackelford; Jerry Lynn | Telescoping die holder |
| JP2014217555A (ja) | 2013-05-08 | 2014-11-20 | ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎａｎｄ Ｃｏｍｐａｎｙ | 輸液チューブセットおよびその使用方法 |
| KR20180122023A (ko) | 2016-03-28 | 2018-11-09 | 어플라이드 머티어리얼스, 인코포레이티드 | 서셉터 지지부 |
| KR20180126316A (ko) | 2017-05-17 | 2018-11-27 | 엘지전자 주식회사 | 스마트 비데 및 이를 포함하는 제어 시스템 |
Non-Patent Citations (1)
| Title |
|---|
| 비특허문헌 1: 일반 사단법인 일본 암 간호학회, 공익 사단법인 일본 임상 종양 학회, 일반 사단법인 일본 임상 종양 약학회 공동편찬, "암 약물 요법에 있어서의 노출 대책 합동 가이드라인 2015년판", 가네하라 출판 주식회사, 2015년 10월 15일 발행, P. 66-68 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114728189A (zh) | 2022-07-08 |
| WO2021095696A1 (ja) | 2021-05-20 |
| JPWO2021095696A1 (enrdf_load_stackoverflow) | 2021-05-20 |
| TW202123978A (zh) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20050186135A1 (en) | Compositions, methods, apparatuses, and systems for singlet oxygen delivery | |
| CA2765696C (en) | Solution containing hypochlorous acid and methods of using same | |
| Ndaw et al. | Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination | |
| KR20080011312A (ko) | 치과용 용도에서 산화 환원 전위 수용액의 사용 방법 | |
| Zhou et al. | Paraquat poisoning by skin absorption: Two case reports and a literature review | |
| KR20130092977A (ko) | 희석된 소독제 용액을 제조하기 위한 장치 | |
| Roussin et al. | Assessment of workplace environmental contamination and occupational exposure to cisplatin and doxorubicin aerosols during electrostatic pressurized intraperitoneal aerosol chemotherapy | |
| KR20220084109A (ko) | 항암제 노출 방지 방법 | |
| US20020098246A1 (en) | Compositions, methods, apparatuses, and systems for singlet oxygen delivery | |
| US20210352905A1 (en) | Compositions and methods to disinfect, treat and prevent microbial infections | |
| JP2020174900A (ja) | 抗癌剤を分解するための薬剤および方法 | |
| JP2024064799A (ja) | 抗がん剤分解液及びこれを用いた抗がん剤分解方法 | |
| KR20010052418A (ko) | 약제용액 조제장치 | |
| JP2024090489A (ja) | 抗がん剤分解液 | |
| JP7012065B2 (ja) | 即効性抗がん剤分解剤及び即効性抗がん剤分解方法 | |
| US20110077572A1 (en) | Medical Equipment and Products using Chlorine, Hydrogen Peroxide, and Anti-Viral, Anti-Bacterial, Anti-Fungal, Agents, usage Method Improvements Dread Disease Cures, Remissions, and Anti-Infective Treatment Measures, Disease Treatment and Prevention System | |
| WO2002078718A2 (en) | Compositions, methods and apparatuses for singlet oxygen delivery | |
| WO2021029347A1 (ja) | 抗がん剤分解剤及び抗がん剤分解方法 | |
| EP3534809B1 (de) | Débridement-vorrichtung | |
| JP3235230U (ja) | 悪臭等防止用パイプ装着おむつ | |
| JP5624446B2 (ja) | 錠剤懸濁投与装置及び錠剤懸濁投与方法 | |
| Turek | Chemotherapy safety in small animal practice: what you need to know to protect yourself, your patient and your clients. | |
| Derry | Iodine: the forgotten weapon against influenza viruses | |
| Dobson | Chemotherapy Protocols and Safety | |
| Grigorescu | Rules for the manipulation of cytostatic agents used in cancerous disease. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20220513 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination | ||
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20250115 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20250325 Comment text: Decision to Refuse Application Patent event code: PE06012S01D |